The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 diabetes and a wider range of CKD is unclear. METHODS: (stage 1 or 2 CKD). Patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary outcome, assessed in a time-to-event analysis, was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. The first secondary outcome was a composite of kidney failure, a sustained decrease from baseline of at least 40% in the eGFR, or death from renal causes. Safety was assessed as investigator-reported adverse events. RESULTS: A total of 7437 patients underwent randomization. Among the patients included in the analysis, during a median follow-up of 3.4 years, a primary outcome event occurred in 458 of 3686 patients (12.4%) in the finerenone group and in 519 of 3666 (14.2%) in the placebo group (hazard ratio, 0.87; 95% confidence interval [CI], 0.76 to 0.98; P = 0.03), with the benefit driven primarily by a lower incidence of hospitalization for heart failure (hazard ratio, 0.71; 95% CI, 0.56 to 0.90). The secondary composite outcome occurred in 350 patients (9.5%) in the finerenone group and in 395 (10.8%) in the placebo group (hazard ratio, 0.87; 95% CI, 0.76 to 1.01). The overall frequency of adverse events did not differ substantially between groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone (1.2%) than with placebo (0.4%). CONCLUSIONS: Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo. (Funded by Bayer; FIGARO-DKD ClinicalTrials.gov number, NCT02545049.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in kidney failure: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with diabetic kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors,3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors,6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone8,9 all reduced the risk of progression to kidney failure.”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) outcome trial (460) demonstrates a significant relationship between reduction in moderately increased albuminuria and reduction in cardiovascular risk.”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [460]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Discontinuation of trial regimen was higher among those on fi nerenone than placebo (1.2% vs. 0.4%).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with T2D and albuminuria are known to be at high risk of CKD progression and cardiovascular events, and the FIDELIO-DKD and FIGARO-DKD trials demonstrated that fi nerenone reduced these events (particularly CKD progression and heart failure) among such patients.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pooled analysis of two complementary trials comprising 13 026 patients with a broad spectrum of CKD and type 2 diabetes, all treated with an optimized dose of an ACEi or ARB,7 , 10 provides robust evidence of both cardiovascular and kidney protection with finerenone vs. placebo.”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People with type 2 diabetes and CKD should be considered for treatment with finerenone to reduce cardiovascular outcomes and the risk of CKD progression (239–242).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finerenone was investigated in two complementary phase 3 studies of patients with T2D, kidney disease (defined primarily as ACR ≥30 mg/g), and potassium <4.8 mmol/L and is the only ns-MRA approved in the world for slowing CKD progression and reducing cardiovascular events.”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in ESKD: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“There was a 13% lower risk of the primary cardiovascular composite outcome, which included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“The secondary composite kidney outcome, which included kidney failure, sustained decrease from baseline of at least 40% in eGFR, or death from kidney causes, was not signi fi cantly different between fi nerenone and placebo (HR 0.87, 95% CI 0.76 -1.01).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“On average, there was only a small reduction in systolic blood pressure (3 mm Hg) with fi nerenone compared to placebo, and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“and fi nerenone reduced the risk of kidney and cardiovascular outcomes in 2 pivotal outcome trials.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the primary cardiovascular composite outcome risk in a broader patient population than studied in FIDELIO-DKD (patients with stage 2–4 CKD and moderately increased albuminuria, or stage 1–2 CKD with severely increased albuminuria).7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The FIDELIO-DKD trial was designed to detect a treatment effect of finerenone on kidney failure endpoints, whereas the FIGARO-DKD trial aimed to detect an effect on a cardiovascular composite primary endpoint.7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76-0.98];P = 0.03) in people with type 2 diabetes and CKD (248).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56-0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56–0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76–0.98]; P = 0.03) in people with type 2 diabetes and CKD (240).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In summary, FIDELIO-DKD and FIGARO-DKD demonstrated cardiovascular and kidney benefits for finerenone among people with T2D who were treated with standard of care (including an RAS inhibitor at maximally tolerated doses and good control of glycemia and BP) who were at high residual risk, based largely on albuminuria (ACR ≥30 mg/g).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Physical activity and aerobic exercise guidelines are similar in persons with T2D independent of lean vs overweight/obese BMI.431,674,727,728”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [431]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overall, the updated evidence review identifi ed 27 RCTs on MRA, with 5 RCTs comparing nonsteroidal MRA to placebo and/or standard of care.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredIn the citing paper
“According to two large randomized placebo-controlled trials targeted at T2DM and CKD patients, finerenone has been demonstrated to significantly reduce the occurrences of composite renal outcome”
In the citing paper
“and composite cardiovascular outcome (defined as a composite of nonfatal MI, nonfatal stroke, death from cardiovascular causes, or hospitalization for heart failure [HHF]), regardless of patients with or without established cardiovascular disease [16, 17].”
In the citing paper
“Even more recently, the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone has been shown to confer both cardiovascular and kidney protection in patients with T2D and CKD, in both a dedicated kidney outcome trial and a dedicated cardiovascular outcome trial [22,23].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [23]
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the composite cardiovascular outcome, which was the primary outcome of the trial (HR: 0.87, 95% CI: 0.76-0.98).26”
In the citing paper
“FIDELIO-DKD and FIGARO-DKD each enrolled people with T2D treated with the maximum-tolerated dose of RASi who had residual albuminuria (ACR $30 mg/g [$3 mg/mmol]) and a nonelevated serum potassium (<4.8 mEq/l at screening).”
In the citing paper
“This recommendation is based on the high-quality evidence from FIDELIO-DKD and FIGARO-DKD (Grade A, summarized above) that finerenone slows progression of CKD and reduces risks of cardiovascular events in this population.25,26”
In the citing paper
“Two large clinical trials (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease [FIDELIO-DKD] 25 and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease [FIGARO-DKD] 26 ) and a pre-specified individual-level combined analysis of these 2 trials (The FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD”
In the citing paper
“To mitigate hyperkalemia risk, the FIDELIO-DKD and FIGARO-DKD trials restricted eligibility to patients with non-elevated serum potassium concentration (after maximizing RASi) and implemented a standardized potassiummonitoring protocol.”
In the citing paper
“The HR of the primary outcome of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization from heart failure was reduced by 13% in patients treated with fi nerenone.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationChronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Self-citationMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationCoresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,000
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Mark, P. B., Sousa‐Amorim, E. D., Eriksson, A. L., Leonsson‐Zachrisson, M., Guzman, N. J., Miller, M. T., Jiang, Y., & Heerspink, H. J. L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf119 · Cited by 10
Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety
Hu, Y., Li, C., Li, S., Xu, L., Wang, Y., & Dong, B. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70075 · Cited by 10
Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
Zhang, Y., Bao, Y.-C., Wang, L.-X., Zhao, H.-J., Sun, J., Sun, L., Duan, W., Du, M., Wang, L., An, Q.-Y., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1667236 · Cited by 10
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
Singh, A. K., Anker, S. D., Pitt, B., Rossing, P. R., Ruilope, L. M., Ahlers, C., Farag, Y. M. K., Lambelet, M., BRINKER, M. D., Rohwedder, K., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.10.032 · Cited by 11
Self-citationGlomerular cell cross talk in diabetic kidney diseases
Dong, R., & Xu, Y. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13304 · Cited by 10
Hirai, T., Ueda, S., Ogura, T., Katayama, K., Dohi, K., Hosohata, K., Aoyama, T., Matsumoto, Y., & Iwamoto, T. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003372 · Cited by 10
Rossing, P. R., Caramori, M. L., Chan, J. C. N., & Al., E. (2023) · KIDNEYS · doi:10.22141/2307-1257.11.4.2022.386 · Cited by 10
Self-citationYuan, Y. E., Haas, A. V., Williams, G. H., Taylor, H. A., Seely, E. W., & Adler, G. K. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028718 · Cited by 11
Piccirillo, F., Liporace, P., Nusca, A., Nafisio, V., Corlianò, A., Magarò, F., Incalzi, R. A., Ussia, G. P., & Grigioni, F. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10060236 · Cited by 10
Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators
Koca, D., & Lother, A. (2023) · Steroids · doi:10.1016/j.steroids.2023.109291 · Cited by 10
Sevre, K., Rist, A., Wachtell, K., Devereux, R. B., Aurigemma, G. P., Smiseth, O. A., Kjeldsen, S. E., Julius, S., Pitt, B., Burnier, M., et al. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad073 · Cited by 10
Self-citationTargeting Pharmacotherapies for Inflammatory and Cardiorenal Endpoints in Kidney Disease
Huck, D. M., Buckley, L. F., Chandraker, A. K., Blankstein, R., & Weber, B. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001482 · Cited by 10
Controversies in Hypertension V: Resistant and Refractory Hypertension
Filippone, E. J., Naccarelli, G. V., & Foy, A. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.09.015 · Cited by 10
New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events
Lavalle, C., Lullo, L. D., Jabbour, J. P., Palombi, M., Trivigno, S., Mariani, M. V., Summaria, F., Severino, P., Badagliacca, R., Miraldi, F., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226956 · Cited by 10
Latest pharmaceutical approaches across the spectrum of heart failure
Bismpos, D., Wintrich, J., Hoevelmann, J., & Böhm, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10389-8 · Cited by 11
Exploring the Mechanism of Cardiorenal Protection with Finerenone Based on Network Pharmacology
Si, Y., Zhu, Y. J., Liu, J., Liu, S., Cai, X., Gu, Y., Li, H., Pan, F., Wang, W., Shangguan, J., et al. (2024) · Cardiorenal Medicine · doi:10.1159/000539393 · Cited by 10
Ming, J., Hong, G., Xu, Y., Mernagh, P., Pochopień, M., & Li, H. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02906-w · Cited by 10
Hu, C., Tkebuchava, T., & Wu, Q. (2024) · Cardiovascular Science · doi:10.35534/cvs.2024.10004 · Cited by 10
Finerenone in the management of diabetes kidney disease
De, P., Khine, M. T., Frankel, A., Goldet, G., Banerjee, D., Montero, R., Chowdhury, T. A., Fogarty, D., Karalliedde, J. J., Mallik, R., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-03985-9 · Cited by 11
Chen, G., Chang, Y. Y., Xiong, Y., Hao, J., Liu, L., Liu, Z., Li, H., Qiang, P., Han, Y., Xian, Y., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108759 · Cited by 10
Scheen, A. J. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2105693 · Cited by 10
Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes
Górriz, J. L., González‐Juanatey, J. R., Fácila, L., Soler, M. J., Valle, A., & Ortíz, A. (2022) · Nefrología · doi:10.1016/j.nefro.2022.09.002 · Cited by 10
Innovations in medical therapy of heart failure with reduced ejection fraction
Mercurio, V., Ambrosio, G., Correale, M., Dini, F. L., Ghio, S., Nodari, S., Palazzuoli, A., Ruocco, G. M., Pedrinelli, R., Mercuro, G. G., et al. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001413 · Cited by 10
Chan, A. T. P., & Tang, S. C. W. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.285 · Cited by 11
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
Prevention of Chronic Kidney Disease and Its Complications in Older Adults
Tungsanga, S., & Bello, A. K. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01128-7 · Cited by 9
Obrador, G. T., Álvarez-Estévez, G., Bellorín-Font, E., Bonanno-Hidalgo, C., Clavero, R., Correa‐Rotter, R., Diná-Batlle, E., Morales, L., Orozco, R., Ortiz, F., et al. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000037 · Cited by 12
Diabetes and Heart Failure: A Literature Review, Reflection and Outlook
Li, X., Zhou, X., & Gao, L. (2024) · Biomedicines · doi:10.3390/biomedicines12071572 · Cited by 10
Yi, Z., Yang, B., Wan, F., Lü, J., Liu, D., Lin, L., Xu, Y., Cen, Z., Fan, M., Liu, W., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118650 · Cited by 9
Varda, L., Ekart, R., Lainščak, M., Maver, U., & Bevc, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169088 · Cited by 9
Gao, Y. J., Liu, X., Gao, Y., Duan, M., Hou, B., & Chen, Y. (2024) · Gut and Liver · doi:10.5009/gnl240038 · Cited by 9
Yi, X., Yang, S., Yang, J., Chen, X., Zhang, A., Zeng, Q., Luo, W., Li, Q., & Hu, J. (2024) · Drugs · doi:10.1007/s40265-024-02092-7 · Cited by 9
Hishida, E., & Nagata, D. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000541939 · Cited by 10
Soulié, M., Stéphan, Y., Durand, M., Lima‐Posada, I., Palacios, R., Nicol, L., López‐Andrés, N., Mulder, P. G. H., & Jaisser, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-74934-z · Cited by 9
Sabina, M., Trube, J., Shah, S., Lurie, A., Grimm, M., & Bizanti, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216398 · Cited by 9
Sex differences in diagnosis and treatment of heart failure: toward precision medicine
Lee, S. Y., & Park, S. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.338 · Cited by 9
Mechanisms and therapeutic potential of multiple forms of programmed cell death in renal fibrosis
Chen, Y., Liu, F., Dai, R., Cheng, M., Wang, W., Sang, Y., Wei, L., Wang, Y., & Zhang, L. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111926 · Cited by 10
Chen, Y., Fang, Y.-W., Chen, M., Liou, H., & Tsai, M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf048 · Cited by 9
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 9
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 9
Anumas, S., & Inagi, R. (2025) · Nephrology · doi:10.1111/nep.70098 · Cited by 11
Tangri, N., Ferguson, T. W., Teng, C., Bamforth, R. J., Smith, J. L., Guzman, M., & Goss, A. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000817 · Cited by 9
Li, F., Han, J., Zhang, W., Lv, J., Wang, Z., Li, H., Jin, L., Feng, J., Lu, W., & Sun, J. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2545939 · Cited by 9
Yau, K., Cherney, D. Z. I., & Odutayo, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70044 · Cited by 9
Chioncel, O., Savarese, G., Laroche, C., Amir, O., Tokmakova, M. P., Cannata, A. N., Do, D. L., Kafafy, T. A., Krejčí, J., Moura, B., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70065 · Cited by 9
Kobayashi, M., Bozkurt, B., Myhre, P. L., López‐Azor, J. C., Guzik, M., Iwanek, G., Baudry, G., Marcos, M. C., Miró, Ò., Dauw, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70079 · Cited by 9
Mounsey, L. A., Chitsazan, M., Shi, I., Ribeiro, P. H., Parekh, J. K., Roshandelpoor, A., Ndumele, C. E., Allen, N. B., Khan, S. S., Psaty, B. M., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5305 · Cited by 9
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction
Valente, V., Beer, B. N., & Savarese, G. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0111 · Cited by 9
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 12
Abdelazeem, B., Elbadawy, M. A., Awad, A. K., Kheiri, B., & Kunadi, A. R. (2022) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2020.01008 · Cited by 9
Sato, A., & Nishimoto, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-00940-1 · Cited by 9
Gnudi, L. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104159 · Cited by 10
Packer, M., Siddiqi, T. J., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad158 · Cited by 9
Bramlage, P., Lanzinger, S., Mühldorfer, S., Milek, K., Gillessen, A., Veith, R., Ohde, T., Danne, T., Holl, R. W., & Seufert, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01840-5 · Cited by 9
Vizcaya, D., Kovesdy, C. P., Reyes, A., Pessina, E., Pujol, P., James, G., & Oberprieler, N. G. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0076 · Cited by 9
Rossing, P. R., Groehl, F., Mernagh, P., Folkerts, K., Garreta-Rufas, A., Harris, J., Meredith, K., Carter, M., Åkerborg, Ö., Wanner, C., et al. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2235922 · Cited by 9
Self-citationYasmin, F., Aamir, M. B., Najeeb, H., Atif, A. R., Siddiqui, A. H., Ahsan, M. N., Moeed, A., Ali, S. H., Tahir, H. M., & Asghar, M. S. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001180 · Cited by 11
Mogi, M., Tanaka, A., Node, K., Tomitani, N., Hoshide, S., Narita, K., Nozato, Y., Katsurada, K., Maruhashi, T., Higashi, Y., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01398-5 · Cited by 9
Novel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Møller, S. H., Kofod, D. H., Schou, M., Torp-Pedersen, C. T., Gislason, G., Carlson, N., & Lindhardt, M. K. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003639 · Cited by 9
Spasovski, G. B., Rroji, M., Hristov, G., Bushljetikj, O., Spahia, N., & Bushletikj, I. R. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0227 · Cited by 9
Mineralocorticoid receptor overactivation in diabetes mellitus: role of O-GlcNAc modification
Jo, R., Itoh, H., & Shibata, H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01734-3 · Cited by 9
Challenges in Diagnosing and Managing the Spectrum of Primary Aldosteronism
Yang, J., McCarthy, J., Shah, S. S., Ng, E., Shen, J., Libianto, R., & Fuller, P. J. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae109 · Cited by 10
Al‐Chalabi, S., Sinha, S., & Kalra, P. A. (2024) · Diabetic Medicine · doi:10.1111/dme.15403 · Cited by 12
Blazek, O., & Bakris, G. L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176752 · Cited by 9
Self-citationOlsen, E., Jamerson, K., Schmieder, R. E., Søraas, C. L., Mariampillai, J. E., Mancia, G., Kjeldsen, S. E., Heimark, S., Mehlum, M. H., Liestøl, K., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.12.021 · Cited by 10
Laborante, R., Delvinioti, A., Tudor, A. M., Lenkowicz, J., Iacomini, C., Iaconelli, A., Paglianiti, D. A., Galli, M., Rodolico, D., Patarnello, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088998 · Cited by 9
Aldosterone synthase inhibition in chronic kidney disease
Theodorakopoulou, M. P., Iatridi, F., & Sarafidis, P. A. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001089 · Cited by 9
Recent advances in the pharmacotherapeutic management of diabetic kidney disease
Block, T. J., Batu, D., & Cooper, M. E. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2054699 · Cited by 9
Progress in the management of patients with diabetes and chronic kidney disease
Garcia, L. P., Thomas, S. S., Rajesh, H., & Navaneethan, S. D. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000811 · Cited by 9
Nicholas, S. B., Wright, E. E., Billings, L. K., Ambriz, E., Gee, P. O., & Peeler, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02325-9 · Cited by 9
Gu, X., Jiang, S., Yang, Y., & Li, W. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01251-2 · Cited by 11
Singh, A. K., & Singh, R. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i7.471 · Cited by 9
New Landmarks to Slow the Progression of Chronic Kidney Disease
Simonini, M., & Vezzoli, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010002 · Cited by 9
Flack, J. M., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P. R., Adler, S. G., Fried, L. F., Jamerson, K., Toto, R. D., et al. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100730 · Cited by 8
Self-citationUpdates in Chronic Kidney Disease
Johnson, H. N., & Prasad‐Reddy, L. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241262381 · Cited by 8
Svensson, M. K. E., Fischereder, M., Kalra, P. R., Sánchez-Lázaro, I. J., Lesén, E., Franzén, S., Allum, A. M., Cars, T., Kossack, N., Breitbart, P., et al. (2024) · Kidney360 · doi:10.34067/kid.0000000000000561 · Cited by 8
Schwartz, S. S., Corkey, B. E., Gavin, J. R., DeFronzo, R. A., & Herman, M. E. (2024) · BMC Medicine · doi:10.1186/s12916-024-03518-5 · Cited by 8
Effect of Finerenone in Cardiovascular and Renal Outcomes: A Systematic Review and Meta-analysis
Rivera-Martinez, J. C., Sabina, M., Khanani, A., Lurie, A., Rigdon, A., Abusnina, W. A., Rosado, L. D. L., Bizanti, A., & Paul, T. K. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07666-x · Cited by 8
Yuan, Y. E., Haas, A. V., ROSNER, B. A., Williams, G. H., McDonnell, M. E., & Adler, G. K. (2025) · Obesity · doi:10.1002/oby.24218 · Cited by 8
STOUGAARD, E. B., Curovic, V. R., & Hansen, T. W. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01726-7 · Cited by 9
Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension
Schinzari, F., Montenero, R., Cardillo, C., & Tesauro, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040790 · Cited by 8
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicoechea, M., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.04.005 · Cited by 10
Wada, T., Anker, S. D., Liu, Z., Lee, B., Lee, C., Rossing, P. R., Ruilope, L. M., Ahlers, C., BRINKER, M. D., Mann, A., et al. (2025) · Kidney Diseases · doi:10.1159/000545415 · Cited by 8
Self-citationFinerenone in Primary IgA Nephropathy: A Matched Case-Control Study
Ouyang, Y., Weng, Q., Zhu, X., Chen, Z., Du, W., Zhao, Q., Xu, J., Hu, X., Wang, Z., & Xie, J. (2025) · Kidney Diseases · doi:10.1159/000546536 · Cited by 8
Li, Y., Feng, J., Guo, X., Zhang, W., Yang, T., Guan, T., & Xu, B. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04241-w · Cited by 8
Watanabe, S., Nakayama, M., Yokoo, T., Sanada, S., Ubara, Y., Komatsuda, A., Asanuma, K., Suzuki, Y., Konta, T., Kazama, J. J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw3934 · Cited by 8
de Moraes, T. P., Moura, A. F., Sposito, A. C., Lopes, F. P. P. L., QUADROS, A. R. D. A., Gadelha, V., Eliaschewitz, F. G., Bertoluci, M. C., Samaan, F., Montenegro, C., et al. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0231en · Cited by 8
Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives
Varda, L., Vreča, N., Ekart, R., Bevc, S., & Piko, N. (2026) · Kidney & Blood Pressure Research · doi:10.1159/000550085 · Cited by 9
Emerging therapeutic pipelines on kidney fibrosis: challenges in translational research
Granata, S., Barberio, L., D’Agostino, R., Sorace, F., Leone, F., Pellegrino, D., Stallone, G., Provenzano, M., & Zaza, G. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07796-w · Cited by 8
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis
Pabón, M. A., Ostrominski, J. W., Wang, X., Claggett, B. L., Lo, K. B., Filippatos, G. S., Desai, A. S., Jhund, P. S., Henderson, A., Lam, C. S. P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag162 · Cited by 8
Self-citationValue of SGLT-2 inhibitors in the treatment of chronic kidney disease
Säemann, M. D., Cejka, D., Schmaldienst, S., Rosenkranz, A. R., & Mayer, G. J. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02096-x · Cited by 9
Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
Rahman, A., Jahan, N., Rahman, M. T., & Nishiyama, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031922 · Cited by 8
Recent progress in the diagnosis and treatment of primary aldosteronism
Yoshida, Y., & Shibata, H. (2023) · Hypertension Research · doi:10.1038/s41440-023-01288-w · Cited by 8
Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease
Bayne, S., LeFevre, J., Olstinske, K., Ravindran, S., & Munusamy, S. (2023) · Advanced Biology · doi:10.1002/adbi.202300496 · Cited by 8
Investigational new drugs for the treatment of chronic renal failure: an overview of the literature
Terzo, C., Gembillo, G., Cernaro, V., Longhitano, E., Calabrese, V., Casuscelli, C., Peritore, L., & Santoro, D. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326624 · Cited by 8
Improving Kidney Disease Care: One Giant Leap for Nephrology
Provenzano, M., Hu, L., Tringali, E., Senatore, M., Talarico, R., Dio, M. D., Ruotolo, C., Manna, G. L., Garofalo, C., & Zaza, G. (2024) · Biomedicines · doi:10.3390/biomedicines12040828 · Cited by 8
Yang, S., Zhao, X., Zhang, J., Liu, H., Wang, Y., & Wang, Y.-G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1429261 · Cited by 8
Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction
Palazzuoli, A., Severino, P., D’Amato, A., Myftari, V., Tricarico, L., Correale, M., Dattilo, G., Fioretti, F., & Nodari, S. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507270 · Cited by 9
Metadata
- Authors
- Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-09
- Volume
- 385
- Issue
- 24
- Pages
- 2252-2263
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3194763937
- Cited by
- 1,814
- References
- 32
- Citations by year
- 2026: 439 · 2025: 435 · 2024: 331 · 2023: 315 · 2022: 250 · 2021: 41
- FWCI
- 160.23
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- National University of Singapore (submittedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Bayer (ClinicalTrials.gov NCT02545049)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- mineralocorticoid receptor antagonists, type 2 diabetes, chronic kidney disease, cardiovascular events, heart failure hospitalization, albuminuria, renin-angiotensin system blockade, hyperkalemia, estimated glomerular filtration rate decline, renal failure, cardiorenal outcomes, FIDELIO-DKD
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Proportional Hazards Models, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
